Protagonist Therapeutics Inc
NASDAQ:PTGX

  • LAST PRICE
    26.6100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    26.0000/ 2
  • Ask / Lots
    35.0000/ 5
  • Open / Previous Close
    0.0000 / 26.6100
  • Day Range
    ---
  • 52 Week Range
    13.7200
    33.3400
  • Volume
    5

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
PTGX
Protagonist Therapeutics Inc
1.6B
-18.1x
---
RXRX
Recursion Pharmaceuticals Inc
1.8B
-4.8x
---
AGIO
Agios Pharmaceuticals Inc
1.7B
-4.8x
---
INBX
Inhibrx Inc
1.6B
-6.8x
---
ARDX
Ardelyx Inc
1.5B
-21.4x
---
FDMT
4D Molecular Therapeutics Inc
1.4B
-10.2x
---
As of 2024-04-23

Company Information

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

Contact Information

Headquarters
7707 Gateway Blvd Ste 140NEWARK, CA, United States 94560-1160
Phone
510-474-0170
Fax
302-636-5454

Executives

Independent Chairman of the Board
Harold Selick
President, Chief Executive Officer, Interim Principal Financial Officer, Director
Dinesh Patel
Chief Financial Officer, Executive Vice President
Asif Ali
Executive Vice President of Clinical Pharmacology and Clinical Operations
Suneel Gupta
Chief Medical Officer
Arturo Molina

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.6B
Revenue (TTM)
$60.0M
Shares Outstanding
58.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.05
EPS
$-1.47
Book Value
$5.83
P/E Ratio
-18.1x
Price/Sales (TTM)
25.8
Price/Cash Flow (TTM)
---
Operating Margin
-156.09%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.